Skip to main content

Advertisement

Table 2 Log-rank, univariate and multivariate associations with OS for clinical variables and genomic characteristics for 176 primary HER2+ tumors

From: High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer

Investigated covariatea Number tumors Log-rank P Univariate P Multivariate P b
ER+ vs. ER- 64/112 0.96 0.96 0.79
LN+ vs. LN- 110/65 4 × 10-6 *** 9 × 10-6 *** 0.0002***
Size >20 mm vs. ≤ 20 mm 122/49 0.002** 0.002** 0.02*
Histological grade 3 vs. 1 and 2 37/26 0.91 0.91 0.83
Age <50 vs. ≥50 years 73/103 0.22 0.23 0.77
DNA Aneuploid vs. Diploid 106/37 0.001** 0.001** 0.005**
DNA Aneuploid vs. Diploid ER+ 37/11 0.008** 0.02* 0.07
DNA Aneuploid vs. Diploid ER- 69/26 0.05* 0.05* 0.06
Recurrent 17q amplification, yes vs. no 70/106 0.17 0.17 0.13
Recurrent amplification excluding 17q, yes vs. no 76/100 0.75 0.75 0.7
Firestorm pattern, yes vs. no 78/98 0.27 0.28 0.58
High FGA vs. low FGAc 42/46 0.08 0.09 0.25
High FGA vs. low FGA ER+ tumorsc 18/17 0.09 0.09 0.26
High FGA vs. low FGA ER- tumorsc 24/29 0.37 0.37 0.55
  1. a Variables with worst outcome highlighted in bold for covariates significantly associated with OS.b Multivariate analysis included LN status and stratified tumor size besides the tested covariate.c High and Low FGA defined as >75th percentile and <25th percentile of all FGA values respectively.
  2. *: Significant at P < 0.05
  3. **: Significant at P < 0.01
  4. ***: Significant at P < 0.001